Lats2 is a new member of the Lats tumor suppressor family. The human LATS2 gene is located at chromosome 13q11-12, which has been shown to be a hot spot (67%) for LOH in nonsmall cell lung cancer. In order to understand the function of LATS2 in the control of tumor development, we ectopically expressed mouse Lats2 via retroviral infection in NIH3T3/v-ras cells to examine whether Lats2 plays a role in suppressing tumor development and regulating cell proliferation. We have found that ectopic expression of Lats2 in NIH3T3/v-ras cells suppresses development of tumors in athymic nude mice and inhibits proliferation of NIH3T3/v-ras cells in an in vitro assay. Cell cycle profile analysis demonstrated that ectopic expression of Lats2 inhibited the G1/S transition. Further mechanistic studies revealed that cyclin E/CDK2 kinase activity was downregulated in Lats2-transduced NIH3T3/v-ras cells, while other cell cycle regulators controlling the G1/S transition were not affected. We have also shown that LATS2 kinase activity and two LATS conserved domains (LCDs) are required for Lats2 to suppress tumorigenicity and to inhibit cell growth. In addition, the LATS2 protein is cytoplasmic during interphase in NIH3T3 cells, while it becomes localized to the mitotic apparatus during mitosis. Finally, we propose a model in which a combination of mammalian Lats2 and Lats1 control cell proliferation by negatively regulating different cell cycle check points.
Introduction
The Lats tumor suppressor family has been shown to play important roles in the control of tumor development and the cell cycles from flies (Justice et al., 1995; Xu et al., 1995) to human (Nishiyama et al., 1999; St John et al., 1999; Tao et al., 1999; Yang et al., 2001; Xia et al., 2002) . Loss of function of Drosophila lats (or warts) results in tumor development in mosaic flies and causes embryonic or pupae lethality in lats homozygotes (Justice et al., 1995; Xu et al., 1995) . LATS1 (or WARTS1), a human homolog of Drosophila lats, is able to rescue all developmental defects in lats homozygous mutants and suppress tumor formation in lats mosaic flies . Lats1-deficient female mice spontaneously develop soft tissue sarcomas and ovarian stromal cell tumors, demonstrating that the Lats1 gene functions as a tumor suppressor in mice . No somatic mutations in the LATS1 coding region have been identified by RT-PCR SSCP analysis of 25 breast cancer samples, although this also does not rule out the possibility that LATS1 may be inactivated in human breast tumors by other epigenetic mechanisms such as methylation (Morinaga et al., 2000) .
Mechanistic studies on LATS1 revealed that it might control tumorigenesis by negatively regulating the cell cycle. The LATS1 protein associates with a major mitotic kinase, CDC2, at G2/M transition or in early mitosis in HeLa cells. CDC2, when associated with LATS1, was found to be inactive for its kinase activity . Loss of function of lats in Drosophila resulted in the upregulation of Cyclin A . Ectopic expression of Lats1 in human cancer cell lines leads to the downregulation of Cyclin A and Cyclin B at the protein level (Xia et al., 2002) and/or inactivation of CDC2 kinase, thereby blocking cells at G2/M and preventing tumor development in nude mice (Yang et al., 2001; Xia et al., 2002) . Microinjection of a truncated human LATS1 protein (a.a 136-700) interfered with the localization of zyxin to the mitotic apparatus and lengthened mitosis . Ectopic expression of LATS1 in human tumor cell lines has also been shown to induce apoptosis by upregulating the level of BAX protein (Xia et al., 2002) or upregulating Caspase-3 activity (Yang et al., 2001) , indicating that LATS1 may also control tumorigenesis by inducing apoptosis.
Lats2 (Yabuta et al., 2000) , also known as KPM (Hori et al., 2000) , is the second mammalian member of the Lats tumor suppressor gene family. Human LATS2 has been mapped onto human chromosome 13q11-12 (Yabuta et al., 2000) , a hot spot (67%) for LOH in nonsmall cell lung cancer (Girard et al., 2000) . Lats2 encodes a putative Ser/Thr protein kinase. The LATS2 protein shares 85% and 75% sequence identity to human LATS1 and Drosophila lats proteins in the kinase domain (Hori et al., 2000; Yabuta et al., 2000) . Although the overall sequence similarity in the amino terminus between mammalian LATS1 and LATS2 proteins is low, two stretches of highly conserved sequence (B50% identical amino acids) are identifiable (Hori et al., 2000 and Figure 4d ). The function of these two conserved domains remains to be unveiled. Although the human LATS2 protein is claimed to be phosphorylated in mitosis, transient transfection of wild-type Lats2 and mutant Lats2 K697A (kinase-inactive) into 293 and HeLa cells revealed no information about the role of Lats2 in the control of cell proliferation and/ or the cell cycle (Hori et al., 2000) . Therefore, it is unknown if the LATS2 gene functions as a tumor suppressor. It is also unclear if LATS1 and LATS2 play different roles in the control of tumor development and the cell cycle. Here, we present evidence that Lats2 has a tumor suppressor function by showing that ectopic expression of Lats2 suppresses tumorigenicity of NIH3T3/v-ras cells and inhibits cell growth. Interestingly, we found that Lats2 controls cell proliferation by negatively regulating the G1/S transition, which is different from the G2/M blockage imposed by LATS1. Our studies reveal that ectopic expression of Lats2 results in a downregulation of Cyclin E/CDK2 kinase activity. We also demonstrate that LATS2 kinase activity and two LATS conserved domains (LCDs) are required for its ability to inhibit cell proliferation and tumorigenicity. Finally, we show that the LATS2 protein is cytoplasmic during interphase, while it also locates to the mitotic apparatus during mitosis.
Results

Expression of exogenous Lats2 gene in NIH3T3 cells
In order to study the role of Lats2 in the control of tumorigenesis and cell proliferation, a replicationdefective retrovirus, MIGR1-Lats2, was generated (see Materials and methods), in which the LATS2 protein and EGFP are coexpressed as a bicistron. The expression of endogenous LATS2 protein cannot be detected by Western blot in either NIH3T3/v-ras cells (data not shown) or its parental cell, NIH3T3 (Yabuta et al., 2000) . The expression of exogenous Lats2 was confirmed by Western blot in Lats2-transduced NIH3T3/ v-ras cells ( Figure 1a, lanes 2 and 3) . Using EGFP as a marker, retrovirus-transduced cells can be enriched by FACS for further analysis ( Figure 1a ). All retrovirusinfected cells used in the following experiments were enriched by FACS.
Lats2 suppresses tumorigenicity of NIH3T3/v-ras cells
To examine whether expression of Lats2 is able to suppress the tumorigenicity of tumor cells, mouse NIH3T3/v-ras cells were infected with either MIGR1-Lats2 or the control virus MIGR1. Anchorage-independent growth of NIH3T3/v-ras cells expressing exogenous Lats2 was measured in soft agar, and tumor development in athymic nude mice was examined. We found that expression of Lats2 in NIH3T3/v-ras cells dramatically suppressed colony growth of NIH3T3/v-ras cells in soft agar as compared to the control (Figure 1b) . Ectopic expression of LATS2 in NIH3T3/v-ras cells also suppressed v-ras-mediated tumorigenesis in athymic nude mice. Our results showed that Lats2-transduced NIH3T3/v-ras cells failed to develop tumors in nude mice (six out of six) 2 weeks after inoculation, while control virus-transduced cells developed large tumors in mice (six out of six). These studies demonstrate that ectopic expression of Lats2 suppressed the anchorageindependent growth of NIH3T3/v-ras cells in soft agar and the tumorigenicity of NIH3T3/v-ras cells in vivo, indicating that Lats2 may play a role in preventing tumor development.
Lats2 inhibits cell proliferation by blocking G1/S transition
To understand the mechanism(s) by which the expression of Lats2 suppresses the tumorigenicity of NIH3T3/ v-ras cells, we examined the effects of ectopic expression of Lats2 on cell proliferation. As shown in Figure 1c , growth of Lats2-transduced NIH3T3/v-ras cells was strongly inhibited compared to the control virustransduced cells. Over a 7-day period, the total cell number of Lats2-transduced NIH3T3/v-ras cells only increased 30-fold, while the control cells increased 210-fold. These results suggest that Lats2, like the LATS1 tumor suppressor, may be another negative cell cycle regulator. To further study the role of Lats2 in cell cycle control, the effects of ectopic expression of Lats2 on the cell cycle progression of NIH3T3/v-ras cells were In total, 7000 of the Lats2-transduced NIH3T3/vras cells or control cells were plated in a 6 cm dish. Total cell numbers were counted daily for 7 days. Experiments were repeated more than three times Lats 2, a putative tumor suppressor Y Li et al examined. NIH3T3/v-ras cells infected with MIGR1-Lats2 or the MIGR1 control virus were first synchronized at G1/S transition by aphidicolin treatment (see Materials and Methods). The cell cycle progression of the cells released from a G1/S block was examined by DNA content FACS analysis (Figure 2a) . Results showed that the control virus-transduced cells entered S phase 1.5 h after being released from the G1/S block, while Lats2-transduced cells had just started DNA synthesis at 2.5 h after the removal of aphidicolin. These data suggest that ectopic expression of Lats2 may block or retard initiation of DNA synthesis. However, data from the DNA content FACS analysis ( Figure 2a ) did not rule out the possibility that Lats2 reduced the DNA synthesis rate. To determine whether Lats2 plays a role in the control of initiation of S phase or the control of the DNA synthesis rate, DNA synthesis was measured in the synchronized Lats2-transduced NIH3T3/v-ras cells and the control cells. First, cells were blocked at G 0 /G1 by serum starvation. After cells reentered the cell cycle by serum stimulation, they were pulse-labeled by BrdU for 1.5 h at the indicated time points (Figure 2b ), and then harvested for measuring the BrdU-positive cells by FACS (see Materials and methods). As shown in Figure 2b , B25% of control cells were labeled by BrdU 8 h after serum stimulation, indicating they had entered S phase. However, o1% of the LATS2-transduced cells were BrdU positive. At 12.5 h after serum stimulation, 58% of the control cells and B30% of the Lats2-transduced cells were in S phase. However, 25% of the BrdU-positive control cells were already at late S phase or G2/M (DNA content r4N), while o5% of Lats2-transduced cells were at late S phase or G2/M ( Figure 2c ). These results further confirmed that initiation of DNA synthesis in Lats2-transduced cells is partially blocked or retarded. About 16 h after serum stimulation, an almost equal amount of Lats2-transduced and control cells were labeled by BrdU ( Figure 2b ). DNA synthesis rate can be measured by the fluorescence intensity of BrdU incorporated into newly synthesized DNA. The intensity of BrdU staining of Lats2-transduced cells will be lower than that of the control cells if ectopic expression of Lats2 reduces the DNA synthesis rate. However, the intensity of the BrdU staining in the control or Lats2-transduced cells was not significantly different (Figure 2c ), suggesting that the rate of DNA synthesis is very similar between control cells and Lats2-transduced cells. These observations indicate that ectopically expressed LATS2 protein has little or no effect on the DNA synthesis rate. Therefore, we conclude that Lats2 negatively regulates the initiation of DNA synthesis.
Lats2 regulates G1/S transition by modulating the kinase activity of Cyclin E/CDK2
To further investigate the molecular mechanisms by which Lats2 regulates G1/S transition, we examined the protein levels of cell cycle regulators that have been implicated in the control of G1/S transition. While ectopic expression of LATS1 in MCF-7 cells resulted in the degradation of Cyclins A and B (Xia et al., 2002) , ectopic expression of Lats2 in NIH3T3/v-ras cells caused no significant changes at the protein level of G1/S regulators such as Cyclin E, Cyclin A and CDK2, nor of negative cell cycle regulators such as P21 WARF1/CIP1 , p27 KIP1 and p57 KIP2 (Figure 3a) . Further in vitro kinase assays revealed that the kinase activity of Cyclin E/ CDK2 was downregulated in Lats2-transduced NIH3T3/v-ras cells as compared to control virustransduced cells (Figure 3b) . However, the kinase activities of Cyclin D/CDK4/6, which are also involved in the control of G1 progression (Sherr, 1996; Sherr and Roberts, 1999) , were not affected (data not shown). Lats2 encodes an active kinase and Lats2 K655M is a kinase-inactive mutant (Hori et al.) . The expression of K697A , see Hori, et al.) failed to down regulate the kinase activity of Cyclin E/CDK2 (Figure 3b ), demonstrating that an active kinase of LATS2 is responsible for inhibiting the activity of Cyclin E/CDK2. All of these results suggest that Lats2 negatively regulates G1/ S transition by directly or indirectly modulating the kinase activity of Cyclin E/CDK2.
Requirement of kinase activity of LATS2 and LCD domains
Lats2 encodes a Ser/Thr protein kinase (Hori et al., 2000; Yabuta et al., 2000) , and the LATS2 protein is phosphorylated in a cell cycle-dependent manner (Hori et al., 2000) . Lys 655 of LATS2 is conserved in the kinase domain of all Ser/Thr kinases (equivalent to Lys72 defined in Hanks et al., 1988) . This conserved Lys residue is essential for the recognition of the phosphate group of Mg-ATP (Hanks et al., 1988) . Mutating this Lys residue usually results in a catalytically inactive protein. Ser 830 of LATS2 is another residue conserved in subdomain eight of the kinase domain (Hanks et al., 1988) . This conserved amino-acid residue is usually phosphorylated to regulate its kinase activity. To test whether the kinase activity of the LATS2 protein is necessary for its tumor suppressor function, two point mutants, Lats2 K655M and Lats2
S830A
, were created and expressed in NIH3T3/v-ras cells using the same retroviral vector, MIGR1 (Figure 4a) . Expression of the two LATS2 mutant proteins, LATS2 K655M and LATS2 S830A , failed to suppress NIH3T3/v-ras cells from forming colonies in soft agar (Figure 4b ). The growth inhibition assay also demonstrates that LATS2 K655M and LATS2-S830A lose their ability to inhibit cell growth (Figure 4c ). These data reveal that the kinase activity of the LATS2 protein is required for suppressing tumorigenicity and inhibiting cell proliferation. K655M , Lats2 S830A , Lats2DLCD1, and Lats2DLCD2, as well as the control virus MIGR1. Expression of LATS2 protein and its mutants were confirmed by Western blot using anti-MYC antibody (a). The methods for soft agar colony formation assay (b) and growth inhibition assay (c) are the same as described in Figure 1 . Cell numbers seeded at day 1 and total cell numbers at day 5 are shown in panel (c). All experiments were repeated three times. Alignment of the amino acid sequence of LCD1 and LCD2 from human LATS1, mouse LATS1, human LATS2 and mouse LATS2 (d). Identical amino acids are shaded in gray. The amino-acid sequence of mouse LATS1 protein was composed of two stretches of sequences from GenBank, a.a. 1-168 was deduced from a mouse genome sequence (Accession NW_000023) according to sequence homology to human LATS1, and the rest was from a mouse cDNA (Accession AAD16883) Lats 2, a putative tumor suppressor Y Li et al There are two stretches of highly conserved sequence (B50% identical amino acids) in the amino-terminus between LATS1and LATS2 (Hori et al., 2000; Yabuta et al., 2000) . For the convenience of description, these two conserved sequences are named as LATS conserved domain 1 (LCD1) and LATS conserved domain 2 (LCD2). The alignment of LCD1 and LCD2 in four mammalian LATS proteins is shown in Figure 4d . LCD2 is also conserved among mammalian LATS and Drosophila lats proteins (data not shown). To examine the necessity of LCD1 and LCD2 for the function of the Lats2 tumor suppressor, two Lats2 mutant retroviruses, MIGR1-Lats2DLCD1 and MIGR1-Lats2DLCD2, were generated, in which either LCD1 or LCD2 was deleted (see Materials and methods). The results shown in Figure 4b and c demonstrate that deleting LCD1 or LCD2 leads to the inability of LATS2 to suppress the tumorigenicity of NIH3T3/v-ras cells and to inhibit cell growth. This indicates that the two LATS conserved domains, LCD1 and LCD2, are required for the normal function of Lats2 in the suppression of tumor development.
The LATS2 proteins are associated with mitotic apparatus in mitotic cells
Human LATS1 protein was shown to be associated with the mitotic apparatus, suggesting a potential role of LATS1 in mitosis . To explore if Lats2 also plays a role in mitosis, we examined cellular localization of ectopically expressed LATS2. Surprisingly, the majority of exogenous LATS2 was localized in the cytoplasm, while there was only very faint LATS2 staining in the nucleus of interphase cells (a-c in Figure 5A ). This result was further confirmed by subcellular fractionation experiments showing that endogenous LATS2 proteins in human lung cancer cells, H661 and H460, are mainly cytoplasmic ( Figure 5B ). We also observed that a fraction of exogenous LATS2 protein was associated with the mitotic apparatus in mitosis, in addition to cytoplasmic localization (d-l in Figure 5A ). This result suggests that Lats2 may also play a role in the regulation of mitosis. More detailed studies are needed to further understand the roles of the LATS1 and LATS2 in mitosis.
Discussion
Drosophila lats and mouse Lats1 genes have been shown to play important roles in suppressing tumorigenesis in flies and mice (Justice et al., 1995; Xu et al., 1995; St John et al., 1999; Tao et al., 1999) . The human LATS2 gene is located at chromosome 13q11-12 (Yabuta et al., 2000) , a hot spot (67%) of LOH for nonsmall cell lung cancer (Girard et al., 2000) , raising the possibility that LATS2 may play an important role in the control of human tumor development. Here, we have demonstrated that ectopic expression of Lats2 suppressed the ability of NIH3T3/vras cells to develop tumors in athymic nude mice and to form colonies in soft agar. These results provide the first experimental evidence suggesting that Lats2, like other members of the Lats family, may function as a tumor suppressor in the control of mammalian tumorigenesis.
Drosophila lats genetically interacts with cyclin A and cdc2 in flies. Inactivation of Drosophila lats resulted in the upregulation of cyclin A, without affecting cyclin B . Ectopic expression of the human LATS1 gene in several human tumor cell lines downregulates the protein levels of Cyclins A and B (Xia et al., 2002) and CDC2 kinase activity, thereby arresting cells at G2/M and preventing tumor development (Yang et al., 2001; Xia et al., 2002) . Here, we have shown that and H460, were fragmentated into cytoplasmic (cyto) and nuclear (nuc) fractions using the methods described by Yabuta et al. (2000) . The same volume of cellular and nuclear extracts were loaded for Western blot with anti-LATS2, anti-a-tubulin or anti-GATA2 antibodies Lats 2, a putative tumor suppressor Y Li et al the ectopic expression of Lats2 also inhibits proliferation of NIH3T3/v-ras cells. Cell cycle profile analysis and BrdU-pulse-labeling experiments (Figure 2a-c) revealed that, different from that of LATS1-mediated G2/M arrest (Xia et al., 2002) , ectopic expression of Lats2 inhibited G1/S transition (Figure 2 ) in addition to its potential role in mitosis ( Figure 5 ). Currently, we cannot rule out the possibility that the different effects of LATS1 and Lats2 on the cell cycle are due to the different cell lines used for the studies. However, the possibility seems unlikely because we have also observed that the human lung cancer cell line, H460, displays similar growth inhibition when it is transduced by MIGR1-Lats2 retrovirus (data not shown), while expression of Lats1 in H460 resulted in a G2/M block and induced apoptosis (Xia et al., 2002) . Furthermore, we have found that, unlike LATS1-mediated downregulation of Cyclins A and B, ectopic expression of Lats2 does not affect the protein levels of the cell cycle regulators affecting G1/S transition, but downregulates Cyclin E/CDK2 kinase activity (Figure 3 ). The downregulation of Cyclin E/CDK2 kinase activity, without affecting Cyclin D/CDK4/6 kinase activities (data not shown) that are required for G1 progression (Sherr, 1996) , further supports the notion that Lats2 negatively regulates G1/S transition without affecting G1 progression. However, it is not yet clear whether ectopic expression of Lats2 directly or indirectly affects Cyclin E/CDK2 kinase activity. The activation of the Cyclin E/CDK2 kinase is necessary for the initiation of DNA replication (Ekholm & Reed, 2000; Blow, 2001) . Recently, Cyclin E/CDK2 has also been shown to be involved in the regulation of an intra-S phase check point in response to DNA damage (Sherr, 1996; Sanchez et al., 1997; Molinari et al., 2000; Falck et al., 2001) . Therefore, we propose that the two mammalian members of the Lats tumor suppressor family, LATS1 and Lats2, negatively regulate different cell cycle check points by modulating different cell cycle kinases ( Figure 6 ). The LATS1 protein is phosphorylated at G2/M transition, and forms a complex with CDC2 and downregulates the protein level of Cyclins A and B, as well as CDC2 kinase activity (Yang et al., 2001; Xia et al., 2002) . Thus, LATS1 negatively regulates G2/M transition by downregulating CDC2 kinase activity. In contrast, Lats2 inhibits G1/S transition by downregulating Cyclin E/CDK2 activity through some unknown mechanism(s) (Figure 6 ). The activity of Cyclin E/CDK2 can be inhibited by binding to P21 waf1/ cip1 or P27 kip1 (Sherr and Roberts, 1999; Ekholm and Reed, 2000) and by phosphorylation at Tyr15 and Thr14 (Gu et al., 1993; McGowan and Russell, 1993; Morgan, 1995) . Rapid inactivation of Cyclin E/CDK2 through the CHK2-CDC25A-CDK2 pathway has been found to play a critical role in both the G1/S check point (Sanchez et al., 1997; Blomberg and Hoffmann, 1999) and the intra-S phase check point response upon genotoxic stress (Molinari et al., 2000; Falck et al., 2001 Falck et al., , 2002 . However, a more detailed investigation is needed to fully characterize the mechanisms by which LATS2 negatively regulates Cyclin E/CDK2 kinase activity.
Our results from both immunostaining of exogenous LATS2 protein in NIH3T3 cells ( Figure 5A ) and subcellular fractionation of endogenous LATS2 protein in human lung cancer cells ( Figure 5B) showed that the majority of LATS2 protein is located in the cytoplasm, while a very small amount is in the nucleus. Our finding differs from the report that human LATS2 protein is a nuclear protein (Yabuta et al., 2000) . We have tried subcellular fractionation experiment using the same cell line (HeLa) and methods described by Yabuta et al. Owing to the crossreaction of monoclonal anti-LATS2 antibody to the proteins from HeLa cells, we failed to repeat the reported results by direct Western blot using our anti-LATS2 antibody, although we were able to detect a single band of endogenous LATS2 protein in HeLa cells at low level by immunoprecipitation followed by Western blot using the same antibody (data not shown). Therefore, it is still possible that the discrepancy results from the difference among the different cell lines used for the experiments.
In summary, the data presented here indicate that Lats2, a new member of the Lats tumor suppressor family, is a negative cell cycle regulator that inhibits G1/ S transition and may be involved in the control of tumor development.
Materials and methods
Cell cultures
The human embryonic kidney cell line, 293 (high passage), was cultured in Dulbecco's modified eagle's medium (DMEM) Figure 6 Models for mammalian LATS1 and LATS2 tumor suppressors negatively regulating the cell cycle. Lats1 controls G2/ M transition by negatively regulating Cyclin A/CDC2 and/or Cyclin B/CDC2 activities. Lats2 affects G1/S transition by modulating Cyclin E/CDK2 activity Lats 2, a putative tumor suppressor Y Li et al with 10% fetal bovine serum (FBS) at 371C, 5% CO 2 . The vras transformed mouse fibroblast, NIH3T3, was a gift from Dr Richard Jove (University of South Florida) and grown in DMEM with 10% calf bovine serum. Human lung cancer cell lines, H661 and H460, were gifts from Dr Robert Kratzke and were cultured in RPMI1640 with 10% calf bovine serum.
Production of the replication-defective recombinant retrovirus
A mouse Lats2 cDNA fragment containing the whole coding region (a gift from Dr Tian Xu at Yale University) was tagged by an MYC epitope and cloned into an amphotropic retrovirus expression vector MigR1 (Pear et al., 1998) . The resulting plasmid, MigR1-Lats2, and the retrovirus genomic plasmid pCL were cotransfected into high-passage 293 cells using the calcium phosphate precipitation method to produce the replication-defective recombinant retrovirus MIGR1-Lats2. In MIGR1-Lats2
K655M and MIGR1-Lats2
S830A
, two residues in the LATS1 kinase domain, Lys 655 and Ser 830, which are conserved in the kinase domains of all Ser/Thr kinases from yeast to human, were mutated into Met and Ala, respectively, using site-directed mutagenesis (Promega). The plasmid pRTLats2, a derivative of the plasmid MigR1-Lats2 without IRES-EGFP elements, was used to generate a replication-defective Lats2 retrovirus without EGFP, which was used for immunostaining to determine the cellular localization of exogenous LATS2 protein.
Growth inhibition assay
NIH3T3/v-ras cells were infected separately by MIGR1-Lats2, LATS2 mutant retrovirus, or MIGR1 for 4-5 h. The virus infection was repeated once 20-24 h after the first infection. Approximately 60-70% of cells were infected 48 h after the second infection, as determined by flow cytometry using EGFP as a marker. Then, EGFP-positive cells were enriched by FACS. In all, 7000 transduced NIH3T3/v-ras cells were replated in 60 mm dishes and the total number of cells was counted daily using a hemacytometer.
Soft agar and nude mice studies
In total, 500 of the Lats2 or control virus-transduced NIH3T3/ v-ras cells enriched by FACS were plated in 4 ml of 0.4% agarose (SeaPlaque, BioProducts) in DMEM with 10% CBS. The cells grew for 3 weeks at 371C, 5% CO 2 . The colonies were stained with MTT (Aftab et al., 1997) for photographing and colony counting. To access the tumorigenicity of Lats2-transduced NIH3T3/v-ras cells in vivo, 2.75 Â 10 5 of Lats2-transduced cells (in 50 ml of PBS) were injected into the flank of athymic mice. Control virus-transduced cells were injected in separate mice as the control. Tumors were allowed to develop for 2 weeks.
Cell synchronization and cell cycle profile analysis
To synchronize the cells, the method described by Wright et al. (1999) was followed with minor modification. Briefly, Lats2 or control virus-transduced NIH3T3/v-ras cells were first enriched by FACS 48 h after infection, then 1.25 Â 10 5 cells were reseeded in 60 mm dishes coated by 0.01% polylysine for 24 h for recovery. The cells were then serum-starved for 36 h in DMEM. Next, cells were stimulated with 20% FBS, and at the same time, 1 mg/ml of aphidicolin (ICN Biomedicals) was added to block the cells at G1/S. After 16 h, the cells were washed three times with 1 Â PBS to remove excess aphidicolin and 10% CBS DMEM was added. The cells were harvested at various time points (Figure 2a ) and stained with propidium iodide (PI) for DNA content analysis by FACS (Becton Dickinson). All of the data from FACS were analyzed with Cellquest software (Becton Dickinson).
BrdU labeling
The enrichment of Lats2 or control virus-transduced NIH3T3/ v-ras cells and the serum starvation were the same as described above. However, after releasing from G 0 /G1 block, the cells were pulse-labeled by BrdU for 1.5 h at various time points. The harvested cells were stained with PE-conjugated monoclonal anti-BrdU antibody (BD Pharmingen) and analyzed by FACS for the BrdU-positive cells following the manufacturer's instruction (BrdU Flow Kit, BD Pharmingen).
Western blot analysis and kinase assay
Lats2 or control virus-transduced NIH3T3/v-ras cells enriched by FACS were allowed to recover for 24 h. Then, cells were either harvested for Western blot analysis or synchronized at G1/S as described previously for an in vitro kinase assay. The harvested cells were lysed in TG buffer with 1 mm PMSF and 1 Â complete proteinase inhibitors (Roche Molecular Biochemicals). Cell lysate proteins (30-120 mg) were used for Western blot. Anti-MYC antibody (A-14), anti-mouse CDK2(M20), CDK4, Cyclin A, Cyclin E, Cyclin D, p21, p27, p57, and b-actin were purchased from Santa Cruz. An anti-LATS2 monoclonal antibody was a generous gift from Dr Tian Xu at Yale University. For the H1 kinase assay, CDK2 proteins were immunoprecipitated with anti-Cyclin E (M20) from the lysates of cells synchronized at G1/S. CDK4 or CDK6 were immunoprecipitated from nonsynchronized cell lysate with anti-CDK4 or anti-CDK6 antibodies and used to access their kinase activities with Rb-C fusion protein (Cell Signaling) as a substrate. The kinase assay was performed as described by Tao et al. (1999) .
Immunofluorescence staining NIH3T3 cells were transduced by a retrovirus, RT-Lats2-myc. After 48 h later, the cells were fixed in ice-cold 100% methanol for 20 min at À201C and permeabilized for 5 min in 0.1% Triton X-100. The coverslips were washed and blocked in 1% normal goat serum in PBS and incubated with rabbit anti-MYC antibody (10 mg/ml) and/or monoclonal anti-tubulin antibodies for 1 h at room temperature. Then, immunofluorescent staining was performed with Rodamine-conjugated anti-rabbit IgG antibody and/or FITC-conjugated anti-mouse IgG antibody and DAPI (1 mg/ml). The coverslips were washed six times with PBS and mounted. Control staining was performed without primary antibodies (data not shown).
Subcellular fractionation
The methods described by Yabuta et al. for subcellular fractionation were exactly followed. The same volume of cellular and nuclear extracts was used for Western blot. The same membrane was blotted with anti-LATS2 antibody first, then stripped repeatedly for blotting cellular and nuclear protein markers. 
